Positron emission tomography with injection of methionine as a prognostic factor in XXXX .

@entity1 @entity5 @entity11 @entity19421 @entity816 @entity3271
OBJECT: Positron emission tomography with @entity19421 (MET-PET) provides information on the metabolism of @entity11 . The aim of this study was to determine the predictive value of MET-PET in the treatment of @entity1 with @entity11 . METHODS: Since 1992, 85 @entity1 with a World Health Organization (WHO) classification-verified @entity11 underwent PET studies in which MET was injected before (74 cases) or after treatment (11 cases). Analysis of PET data was conducted by the same investigator using two scales: a qualitative visual grading scale and a quantitative scale (ratio between @entity5 uptake and normal brain uptake, classified on a seven-level scale). Uptake of MET was present in 98% of @entity11 . The investigator judged this uptake to be moderate to very high based on visual inspection (qualitative scale). For all grades of @entity11 , a visual grade of 3 was statistically associated with a shorter @entity1 survival period (p < 0.005). The @entity5 /normal brain uptake ratio was significantly influenced by the histological grade of the @entity5 . A statistically poor outcome was demonstrated when this ratio was higher than a threshold of 2.2 for a WHO Grade II @entity5 and 2.8 for WHO @entity5 . For @entity5 , @entity3271 had a higher uptake of MET than @entity816 . CONCLUSIONS: Uptake of MET was present in 98% of the @entity11 studied. A high uptake is statistically associated with a poor survival time. The intensity of MET uptake represents a prognostic factor for WHO @entity5 considered separately.
